Phase 3 Type 2 Diabetes Trial, Recruiting NCT05569772 Sponsor: Universitaire Ziekenhuizen KU Leuven Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT05569772
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older
  • People who had gestational diabetes (diabetes during pregnancy) that was diagnosed using specific 2013 WHO guidelines, either between 24 and 32 weeks of pregnancy, or before 24 weeks in cases of early gestational diabetes
  • People who were diagnosed with prediabetes (blood sugar levels higher than normal but not yet at diabetes levels) between 6 weeks and 12 months after giving birth, based on specific blood sugar test results (confirm with trial site for exact values)
  • People who have stopped breastfeeding
  • People who are not planning to become pregnant within the next year
  • People who are using effective contraception
  • People who are not taking any medications that affect blood sugar levels
  • People who have provided written consent before any study procedures begin

Who may not be able to join:

  • People who already have a confirmed diabetes diagnosis
  • People who have certain immune markers in their blood that suggest type 1 diabetes
  • People whose blood sugar levels are completely normal
  • People with a history of pancreatitis (inflammation of the pancreas)
  • People who have previously had weight-loss (bariatric) surgery, or who have such surgery planned within the next two years
  • People who are unable to understand and speak Dutch, French, or English
  • People who are currently pregnant or planning to become pregnant within one year of taking part in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 16340614

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
14 September 2023
Est. completion
1 June 2029

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Development of T2DM

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov